The backdrop: Rising concern, rising market

Lyme disease, caused primarily by the bacterium Borrelia burgdorferi and transmitted by blacklegged ticks, has expanded geographically with changing environments and greater human–tick contact. As reported by numerous outlets, patient concern has grown alongside reports of persistent symptoms after infection. This environment has fostered a parallel marketplace of unapproved laboratory tests and alternative treatments that promise clearer answers or lasting relief—often without strong evidence or regulatory oversight.

For people who feel unwell and overlooked, these offerings can be deeply appealing. But they can also lead to misdiagnosis, unnecessary or risky interventions, and delays in appropriate care.

How Lyme disease is diagnosed in evidence-based care

In mainstream medical practice, Lyme disease is diagnosed by combining clinical assessment (symptoms, exam findings, and exposure history) with validated laboratory testing when appropriate.

• Early localized disease: A classic erythema migrans rash (the “bull’s‑eye” rash) is sufficient for diagnosis and treatment without waiting for lab confirmation.
• Standard laboratory testing: Validated “two‑tier” or “modified two‑tier” serologic algorithms use FDA‑cleared immunoassays. Antibodies often take several weeks to develop, so timing matters.
• What tests can and cannot do: Approved tests help confirm exposure and infection. No current test can prove that Lyme is the cause of every symptom, and no test can prove cure or persistent infection after recommended treatment.

Because Lyme prevalence varies by region and season, false positives become more likely in low‑prevalence settings. Clinical context is essential to avoid over‑ or under‑diagnosis.

Unapproved or unvalidated tests you may encounter

Some clinics and for‑profit laboratories market tests that have not been cleared or approved by the FDA and are not recommended by major medical guidelines. These may include:

• Nonstandard Western blots or “in‑house criteria” that interpret bands differently from validated algorithms.
• Lymphocyte transformation tests (LTTs) or other immune function assays marketed to detect “active” Lyme.
• CD57 counts promoted as a Lyme activity marker, despite poor specificity.
• Urine antigen tests and unvalidated PCR assays on nonstandard specimens.
• Live blood analysis/dark‑field microscopy claiming to visualize spirochetes in blood without rigorous validation.
• “Energy,” bioresonance, muscle testing, or frequency‑based devices that lack a scientific basis for detecting infection.

Regulators have warned that such tests can yield false positives and false negatives, leading to unnecessary treatment or missed diagnoses of other conditions. Before paying out of pocket, ask whether a test is FDA‑cleared for Lyme diagnosis and whether it is recommended by established guidelines.

Alternative treatments on the rise—and their risks

Alongside unapproved tests, a range of “alternative” or nonstandard treatments are marketed for confirmed or suspected Lyme, especially for persistent symptoms. Examples include:

• Long‑term or combination antibiotics (including repeated IV courses) far beyond guideline‑recommended durations.
• Intravenous therapies such as high‑dose vitamin C, hydrogen peroxide, ozone, or UV blood irradiation.
• Herbal protocols and supplements (e.g., essential oils, cat’s claw, Japanese knotweed) with variable evidence and quality control.
• Disulfiram, dapsone, or other repurposed drugs used off‑label without robust, controlled data on benefits versus harms.
• Hyperbaric oxygen, stem cells, chelation, colloidal silver, Rife machines, or bioresonance therapies lacking convincing clinical evidence for Lyme.
• Bee venom therapy and other approaches with meaningful risk of allergic reactions or other complications.

Reported harms include catheter infections and sepsis, Clostridioides difficile colitis, liver toxicity, arrhythmias, neuropathy, interactions with other medications, and substantial financial cost. For many, these risks outweigh any unproven benefit.

Why this proliferation is happening

• Patient experience: Some people have persistent fatigue, pain, or cognitive complaints after tick‑borne infections or other illnesses. When answers are scarce, alternative pathways flourish.
• Information gaps: Persistent symptoms are real and distressing, but their causes are diverse. The science is still evolving, and uncertainty creates openings for unvalidated claims.
• Market incentives: Cash‑pay diagnostics and therapies can be lucrative. Aggressive online marketing and testimonials amplify reach.
• Social media dynamics: Personal narratives can powerfully influence decisions, even when they don’t generalize or align with high‑quality evidence.

What evidence‑based care looks like today

• Early treatment: For confirmed early Lyme, short courses of antibiotics are highly effective.
• Complicated cases: Neurologic, cardiac, or arthritic manifestations have specific, guideline‑based regimens.
• Persistent symptoms after treatment: Often termed post‑treatment Lyme disease symptoms (PTLDS), these are managed with supportive, symptom‑focused care (e.g., sleep, pain, mood, rehab, pacing), not extended antibiotics, which have not shown consistent benefit in randomized trials.
• Broader evaluation: A careful workup can identify alternative or additional contributors to symptoms (e.g., sleep disorders, anemia, autoimmune disease, thyroid issues, mood disorders, deconditioning, other infections).

How to vet tests and treatments

• Is the diagnostic test FDA‑cleared for Lyme disease and used within a guideline‑supported algorithm?
• Does the clinic provide clear evidence from randomized trials for the proposed therapy, or mainly testimonials?
• What are the known risks, side effects, and total costs? How will safety be monitored?
• Is there a plan to reassess and stop if no objective improvement occurs?
• Have other potential diagnoses been systematically considered?
• Is the provider board‑certified in a relevant specialty and willing to coordinate with your primary clinician?

Bringing a trusted family member to appointments, requesting copies of labs, and seeking a second opinion from an infectious diseases specialist can help you make informed choices.

Recognizing red flags

• Guarantees of a cure or of detecting “hidden Lyme” in everyone with fatigue or pain.
• Pressure to purchase packages upfront, or reluctance to share test performance data.
• Advice to stop all conventional care, or to use IV treatments without clear indications.
• Exclusive reliance on a single unvalidated test to justify months of antibiotics.
• Claims that a therapy works for nearly every chronic condition.

For patients and families: Practical steps

• If you have a new tick bite: Ask a clinician about regional risk and whether a single preventive antibiotic dose is appropriate; monitor for rash or fever.
• If you have a classic erythema migrans rash: Seek prompt treatment—lab tests aren’t needed before starting.
• If symptoms persist after standard therapy: Request a thorough, stepwise evaluation and discuss non‑antibiotic strategies that target sleep, pain, activity pacing, mood, and rehabilitation.
• Before paying out of pocket: Verify test/therapy oversight, evidence, and safety; ask your insurer what’s covered; consider a second opinion.

This information is educational and not a substitute for personalized medical advice. Discuss individual decisions with a qualified clinician who knows your history.

Policy and oversight

Regulatory agencies have cautioned clinicians and the public about unapproved Lyme tests and the risk of false results. Professional societies publish guidelines that are periodically updated as evidence evolves. Continued investment in tick prevention, clinician education, better diagnostics, and rigorous trials for persistent symptoms is essential to reduce uncertainty and patient harm.

Key takeaways

• Validated, guideline‑supported testing and treatment work well for most cases of Lyme disease.
• Unapproved tests and alternative therapies are proliferating but often lack reliable evidence and oversight.
• False diagnoses and risky treatments can cause real harm and delay proper care.
• People with persistent symptoms deserve comprehensive, compassionate, evidence‑based evaluation and support.
• Ask critical questions, seek second opinions, and prioritize safety and proven benefit.